Nicole Chmielewski-Stivers

Articles by Nicole Chmielewski-Stivers

33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX

ByWilliam Audeh, MD,Nicole Chmielewski-Stivers,Harshini Ramaswamy,Andrea Menicucci

June 30th 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer

Real-World Data Reveals Underdiagnosis of SCLC-Associated LEMS

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA

Why Investigate Implant Upsizing in a Mastectomy Skin Flap Necrosis Study?

Can Ropeginterferon Elicit Disease Modification in Essential Thrombocythemia?